Abstract 4295
Background
Founder BRCA1/2 cancer predisposing mutations have been reported in Italian population. We reported the founder BRCA1 mutation, c.4117G>T - p.Glu1373*, recurring in unrelated families of Abruzzo and Lazio regions of Central Italy.
Methods
Preliminary analysis of 17 unrelated families carrying BRCA1 c.4117G>T nonsense mutation reported in the Hereditary Breast/Ovarian Cancer Registry of the Oncology Territorial Care Unit, University of L’Aquila and Genetic Unit, Catholic University of Rome was performed by genetic counselling and peripheral blood collection after written informed consent from affected and unaffected probands. BRCA1/2 genetic analysis were performed by direct sequencing; haplotype analysis was carried out using microsatellite markers in the 17q21 region: D17S846, D17S1328, D17S855 (intragenic), D17S902, D17S806. Post-test genetic counselling was performed to address Therapeutic and/or Preventive Clinical strategies. Geographic area of origin, cancer family trees, cancers affecting the probands were collected. To date, overall 23 unrelated families were enrolled.
Results
In the preliminary analysis, BRCA1 c.4117G>T mutation was identified in 17 unrelated families with familial origin in a territory of Central Italy including Abruzzo and Lazio regions: this mutation was always and significantly associated with the Allelic Variant (AV) BRCA1, c.3119G>A (p.Ser1040Asn), in 52 tested carriers, 20 affected and 32 unaffected. Microsatellite markers confirmed a common haplotype shared by the 52 probands, comprising the region between D17S1328 and D17S902 markers. In overall 23 unrelated families, the association of BRCA1 founder mutation and the AV were identified in 66 tested carriers, 28 affected and 38 unaffected.
Conclusions
The BRCA1 c.4117G>T is a founder mutation prevalent in the territory of Central Italy in Abruzzo and southern Lazio regions, cosegregating with AV BRCA1 c.3119G>A, providing faster identification of affected and unaffected carriers to specifically address therapeutic and preventive clinical pathways for breast, ovarian and BRCA1-related cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Enrico Ricevuto.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3664 - Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract